A Randomised, Placebo-Controlled, Double-blind, Single and Multiple Ascending Dose, Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics Following Intravenous Administration of IRX-010 in Healthy Participants
Phase 1
Active, not recruiting
- Conditions
- Inflammatory diseaseMedDRA version: 20.0Level: LLTClassification code: 10021426Term: Immune system disorder (NOS) Class: 10021428Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Registration Number
- CTIS2023-503917-31-00
- Lead Sponsor
- Immunorx Pharma Inc.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Not Recruiting
- Sex
- All
- Target Recruitment
- 81
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of IRX-010 in targeting immune system disorders?
How does IRX-010 compare to standard-of-care treatments for inflammatory diseases in phase I trials?
Which biomarkers are used to predict response to IRX-010 in healthy participants?
What are the potential adverse events associated with IRX-010 intravenous administration in phase I studies?
Are there related compounds or competitor drugs in Immunorx Pharma's pipeline for immune system disorders?